CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance (Q35980938)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance (English)

1 reference

Europe PubMed Central

11 August 2017

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

M L Linenberger

1

1 reference

Europe PubMed Central

11 August 2017

publication date

1 February 2005

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

19

1 reference

Europe PubMed Central

11 August 2017

2

1 reference

Europe PubMed Central

11 August 2017

176-182

1 reference

Europe PubMed Central

11 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403598

0 references

New agents in acute myeloid leukemia and other myeloid disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

The sialoadhesin CD33 is a myeloid-specific inhibitory receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Cleavage of cellular DNA by calicheamicin gamma1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Cleavage behavior of calicheamicin gamma 1 and calicheamicin T

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Activation of the DNA-dependent protein kinase by drug-induced and radiation-induced DNA strand breaks

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Histone H2A variants H2AX and H2AZ

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Sensitivity of fibroblasts derived from ataxia-telangiectasia patients to calicheamicin gamma 1I.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Differential responses of Chinese hamster mutagen sensitive cell lines to low and high concentrations of calicheamicin and neocarzinostatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Cell-cycle targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

How does P-glycoprotein recognize its substrates?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

The role of drug efflux pumps in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

ABCG2 (BCRP) expression in normal and malignant hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

21 January 2018

The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in CD33 intensity between various myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Salt dependence of calicheamicin-DNA site-specific interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by calicheamicin gamma 1 in human HL-60 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Enediyne-mediated cleavage of RNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Transcriptional effects of the potent enediyne anti-cancer agent Calicheamicin gamma(I)(1)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403598

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403598

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35980938&oldid=1973347236"